


# **ATAGENIX LABORATORIES**

### Catalog Number:ATMP00243HU Recombinant Human CD52 protein ,C- Fc Tag

### **Product Details**

Summary	
English name	Recombinant Human CD52 protein ,C- Fc Tag
Purity	>90% as determined by SDS-PAGE
Endotoxin level	<1.0 EU per $\mu$ g of the protein as determined by the LAL method.
Construction	A DNA sequence encoding the human CD52(Met1-Ser36) was fused with the C-
	terminal Fc Tag
Accession #	P31358
Host	Mammalian cells
Species	Homo sapiens (Human)
Predicted Molecular Mass	29.07kDa
Formulation	Supplied as solution form in PBS pH 7.5 or lyophilized from PBS pH 7.5.
Shipping	In general, proteins are provided as lyophilized powder/frozen liquid. They are
	shipped out with dry ice/blue ice unless customers require otherwise.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles.
	Store at 2 to 8 °C for one week .
	Store at -20 to -80 °C for twelve months from the date of receipt.
Reconstitution	Reconstitute in sterile water for a stock solution.A copy of datasheet will be
	provided with the products, please refer to it for details.

#### SDS-PAGE image



#### Background

Background

CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a

glycoprotein that in humans is encoded by the CD52 gene. It is widely expressed

105-0



# **ATAGENIX LABORATORIES**

## Catalog Number:ATMP00243HU Recombinant Human CD52 protein ,C- Fc Tag

on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for Tcell activation and proliferation. CDW52,HE5,CD52,CAMPATH-1 antigen Trindade, Thaniyavarn, Townsend, Klasek, Tsveybel, Kennedy, Goldberg, El-Chemaly (2020) Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres Frontiers in immunology 11() 1063

#### **Frontier progress**

**Alternative Names** 

References

Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is a form of advanced immunosuppression that is currently used as a therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in lung transplant recipients (1-3). Side effects of alemtuzumab include bone marrow suppression, infection, and malignancy. Whether alemtuzumab can be safely used in allograft recipients that have an increased propensity for bone marrow suppression due to telomeropathies is unknown. In a retrospective case series, we report outcomes associated with alemtuzumab in three lung allograft recipients with short telomere lengths, comparing endpoints such as leukopenia, transfusion needs, infection, hospitalization and survival to those of 17 patients with short telomeres is safe, though is associated with an increased incidence of neutropenia, thrombocytopenia and anemia requiring packed red blood cell transfusions. Alemtuzumab appears to be an acceptable advanced immunosuppressive therapy in patients with telomeropathies, though given the design and scope of this study, the actual clinical effect needs further evaluation in larger trials.